摘要
目的探讨孟鲁司特对过敏性鼻炎患儿血清白细胞介素-13(IL-13)和肿瘤坏死因子(TNF-α)的影响。方法60例过敏性鼻炎患儿随机分为两组,观察组和对照组各30例,对照组单用布地奈德气雾剂治疗,观察组在布地奈德气雾剂治疗基础上加用孟鲁司特。治疗4 w后比较两组疗效,并分别在治疗前后检测两组患儿的血清IL-13与TNF-α水平。结果观察组总有效率为96.6%,对照组为66.7%,两组比较差异有统计学意义(P<0.05)。治疗后两组IL-13和TNF-α均有明显降低,而观察组比对照组降低更明显(P<0.01)。结论孟鲁司特可能通过调节血清IL-13与TNF-α水平而改善过敏性鼻炎患儿的病情。
Objective To explore the effect of montelukast on serum interleukin-13 （IL-13） and tumor necrosis factor （TNF-α） in children with allergic rhinitis. Methods 60 children with allergic rhinitis were divided into observation group and control group （n = 30 per group）. In the control group, budesonide aerosol was used; on the basis of budesonide aerosol, montelukast was used in the observation group. After four weeks of treatment, the curative effects between the two groups were compared. Before and after the treatment, the levels of IL-13 and TNF-α of the children in the two groups were detected. Results The overall efficacy in observation group was 96.6% and that in the control group was 66.7% , so there was a significant difference between two groups （P 〈 0.05）. After the treatment, the levels of IL-13 and TNF-α in both groups decreased obviously, and those in the observation group decreased more obviously than those in the control group （P 〈 0.01）. Conclusion Montelukast may regulate the levels of IL-13 and TNF-α to improve the illness of the children with allergic rhinitis.
出处
《西南国防医药》
CAS
2015年第4期372-374,共3页
Medical Journal of National Defending Forces in Southwest China
